Robert Plenge is a physician-scientist known for his work at Merck, Celgene, and BMS, translating insights from human genetics into breakthroughs in drug discovery and development, resulting in new medicines. On his well-known blog, he writes with inspiring clarity about genomics, therapeutic target validation, and lessons from translational research, bridging academic rigor and industry practice for scientists and clinicians alike. In this interview, we explore Robert's passion for causal human biology, drug development, and leading teams.

Roberts Blog: https://www.robertplenge.com

Coronary heart disease is no longer a mystery. Listen to the story of one of medicine’s greatest triumphs — a battle fought in labs, clinics, kitchens, and boardrooms. This is the story of cholesterol. And how we turned a silent killer into a preventable disease.

Dame Catherine Elizabeth "Kate" Bingham is a British biochemist and life‑sciences venture capitalist. She earned a first‑class MA in Biochemistry from Oxford and an MBA (Baker Scholar) from Harvard. Since 1991, she has been a managing partner at SV Health Investors, co‑founding the Dementia Discovery Fund and helping launch multiple first‑in‑class drugs. In May 2020, she chaired the UK’s Vaccine Taskforce, securing 350 million COVID‑19 doses and leading the country to be the first Western nation to begin vaccinations. Honored as a DBE in 2021, Kate also serves on the Francis Crick Institute and ARIA boards.